{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:27:15Z","timestamp":1787066835951,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41375-025-02711-6","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:39:27Z","timestamp":1753115967000},"page":"2256-2265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy"],"prefix":"10.1038","volume":"39","author":[{"given":"Alexandre","family":"Bazinet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-8405","authenticated-orcid":false,"given":"Yue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naszrin","family":"Arani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Darbaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-4249","authenticated-orcid":false,"given":"Ian","family":"Bouligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthakan","family":"Thongon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-4806","authenticated-orcid":false,"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-4556","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-5176","authenticated-orcid":false,"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"2711_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.stem.2024.05.010","volume":"31","author":"NA Jakobsen","year":"2024","unstructured":"Jakobsen NA, Turkalj S, Zeng AGX, Stoilova B, Metzner M, Rahmig S, et al. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell Stem Cell. 2024;31:1127\u201344.e17.","journal-title":"Cell Stem Cell"},{"key":"2711_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43697-y","volume":"14","author":"J McClatchy","year":"2023","unstructured":"McClatchy J, Strogantsev R, Wolfe E, Lin HY, Mohammadhosseini M, Davis BA, et al. Clonal hematopoiesis related TET2 loss-of-function impedes IL1beta-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat Commun. 2023;14:8102.","journal-title":"Nat Commun"},{"key":"2711_CR3","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1016\/j.celrep.2018.11.056","volume":"25","author":"M Mann","year":"2018","unstructured":"Mann M, Mehta A, de Boer CG, Kowalczyk MS, Lee K, Haldeman P, et al. Heterogeneous responses of hematopoietic stem cells to inflammatory stimuli are altered with age. Cell Rep. 2018;25:2992\u20133005.e5.","journal-title":"Cell Rep"},{"key":"2711_CR4","doi-asserted-by":"publisher","first-page":"107328","DOI":"10.1016\/j.isci.2023.107328","volume":"26","author":"MC Buck","year":"2023","unstructured":"Buck MC, Bast L, Hecker JS, Riviere J, Rothenberg-Thurley M, Vogel L, et al. Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS. iScience. 2023;26:107328.","journal-title":"iScience"},{"key":"2711_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41588-019-0375-1","volume":"51","author":"I Iacobucci","year":"2019","unstructured":"Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51:694\u2013704.","journal-title":"Nat Genet"},{"key":"2711_CR6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood.2020009103","volume":"137","author":"I Iacobucci","year":"2021","unstructured":"Iacobucci I, Qu C, Varotto E, Janke LJ, Yang X, Seth A, et al. Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood. 2021;137:1628\u201340.","journal-title":"Blood"},{"key":"2711_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"2711_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2711_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2711_CR10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/modpathol.2008.142","volume":"21","author":"SA Wang","year":"2008","unstructured":"Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda BA, et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008;21:1394\u2013402.","journal-title":"Mod Pathol"},{"key":"2711_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.leukres.2016.05.006","volume":"47","author":"JM Bennett","year":"2016","unstructured":"Bennett JM, Tuechler H, Aul C, Strupp C, Germing U. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?). Leuk Res. 2016;47:63\u201369.","journal-title":"Leuk Res"},{"key":"2711_CR12","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","volume":"129","author":"G Montalban-Bravo","year":"2017","unstructured":"Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017;129:2584\u20137.","journal-title":"Blood"},{"key":"2711_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00746-x","volume":"12","author":"KK Reichard","year":"2022","unstructured":"Reichard KK, Tefferi A, Abdelmagid M, Orazi A, Alexandres C, Haack J, et al. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood Cancer J. 2022;12:147.","journal-title":"Blood Cancer J"},{"key":"2711_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/ajh.20563","volume":"81","author":"FM Mazzella","year":"2006","unstructured":"Mazzella FM, Smith D, Horn P, Cotelingam JD, Rector JT, Shrit MA, et al. Prognostic significance of pronormoblasts in erythrocyte-predominant myelodysplastic patients. Am J Hematol. 2006;81:484\u201391.","journal-title":"Am J Hematol"},{"key":"2711_CR15","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.3324\/haematol.2018.212563","volume":"104","author":"MF van Spronsen","year":"2019","unstructured":"van Spronsen MF, Westers TM, Lissenberg-Witte BI, Wondergem M, Ossenkoppele GJ, van de Loosdrecht AA. The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?. Haematologica. 2019;104:e547\u201350.","journal-title":"Haematologica"},{"key":"2711_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2711_CR17","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","volume":"9","author":"A Bazinet","year":"2022","unstructured":"Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022;9:e756\u201365.","journal-title":"Lancet Haematol"},{"key":"2711_CR18","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(23)00367-8","volume":"11","author":"A Bataller","year":"2024","unstructured":"Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1\/2 study. Lancet Haematol. 2024;11:e186\u201395.","journal-title":"Lancet Haematol"},{"key":"2711_CR19","doi-asserted-by":"publisher","first-page":"TPS7054","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","volume":"39","author":"AM Zeidan","year":"2021","unstructured":"Zeidan AM, Garcia JS, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z-J, et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes. J Clin Oncol. 2021;39:TPS7054.","journal-title":"J Clin Oncol"},{"key":"2711_CR20","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanmaki","year":"2023","unstructured":"Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa AM, Huuhtanen J, Vanttinen I, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610\u201325.","journal-title":"Blood"},{"key":"2711_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"2711_CR22","first-page":"2679","volume":"130","author":"CY Ok","year":"2017","unstructured":"Ok CY, Singh R, Luthra R, Hatfield D, Floyd K, Loghavi S, et al. Endleukemia Assay v1: enabling NGS-based comprehensive routine molecular profiling of leukemias in routine clinical care. Blood. 2017;130:2679.","journal-title":"Blood"},{"key":"2711_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","volume":"4","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4:482\u201395.","journal-title":"Blood Adv"},{"key":"2711_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.","journal-title":"Genome Biol"},{"key":"2711_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/cyto.b.22140","volume":"104","author":"SA Wang","year":"2023","unstructured":"Wang SA, Jorgensen JL, Hu S, Jia F, Li S, Loghavi S, et al. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal\/measurable residual disease detection. Cytom B Clin Cytom. 2023;104:356\u201366.","journal-title":"Cytom B Clin Cytom"},{"key":"2711_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2711_CR27","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2711_CR28","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"2711_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11\u201324.","journal-title":"Cancer Cell"},{"key":"2711_CR30","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1038\/s41375-022-01727-6","volume":"36","author":"JJ Xu","year":"2022","unstructured":"Xu JJ, Chalk AM, Wall M, Langdon WY, Smeets MF, Walkley CR. Srsf2(P95H\/+) co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice. Leukemia. 2022;36:2883\u201393.","journal-title":"Leukemia"},{"key":"2711_CR31","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"2711_CR32","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41375-020-01075-3","volume":"35","author":"P Sportoletti","year":"2021","unstructured":"Sportoletti P, Sorcini D, Guzman AG, Reyes JM, Stella A, Marra A, et al. Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. Leukemia. 2021;35:1949\u201363.","journal-title":"Leukemia"},{"key":"2711_CR33","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","volume":"55","author":"A Rodriguez-Meira","year":"2023","unstructured":"Rodriguez-Meira A, Norfo R, Wen S, Ch\u00e9deville AL, Rahman H, O\u2019Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55:1531\u201341.","journal-title":"Nat Genet"},{"key":"2711_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI75714","volume":"125","author":"M Byrska-Bishop","year":"2015","unstructured":"Byrska-Bishop M, VanDorn D, Campbell AE, Betensky M, Arca PR, Yao Y, et al. Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus. J Clin Investig. 2015;125:993\u20131005.","journal-title":"J Clin Investig"},{"key":"2711_CR35","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.isci.2020.101018","volume":"23","author":"O Romano","year":"2020","unstructured":"Romano O, Petiti L, Felix T, Meneghini V, Portafax M, Antoniani C, et al. GATA factor-mediated gene regulation in human erythropoiesis. iScience. 2020;23:101018.","journal-title":"iScience"},{"key":"2711_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00858-y","volume":"13","author":"JA Georgi","year":"2023","unstructured":"Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Rollig C, et al. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome. Blood Cancer J. 2023;13:88.","journal-title":"Blood Cancer J"},{"key":"2711_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/s41375-023-01906-z","volume":"37","author":"N Duployez","year":"2023","unstructured":"Duployez N, Vasseur L, Kim R, Largeaud L, Passet M, L\u2019Haridon A, et al. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia. Leukemia. 2023;37:1245\u201353.","journal-title":"Leukemia"},{"key":"2711_CR38","doi-asserted-by":"crossref","unstructured":"Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, et al. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022;28:557\u2013567.","DOI":"10.1038\/s41591-022-01696-4"},{"key":"2711_CR39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"2711_CR40","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349.","journal-title":"Cancer Discov"},{"key":"2711_CR41","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang L, Doherty GA, Judd AS, Tao Z-F, Hansen TM, Frey RR, et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor. ACS Med Chem Lett. 2020;11:1829\u201336.","journal-title":"ACS Med Chem Lett"},{"key":"2711_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.critrevonc.2015.10.013","volume":"98","author":"C Talati","year":"2016","unstructured":"Talati C, Griffiths EA, Wetzler M, Wang ES. Polo-like kinase inhibitors in hematologic malignancies. Crit Rev Oncol Hematol. 2016;98:200\u201310.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2711_CR43","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.2023019782","volume":"142","author":"CH Man","year":"2023","unstructured":"Man CH, Lam W, Dang CC, Zeng XY, Zheng LC, Chan NN, et al. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood. 2023;142:2002\u201315.","journal-title":"Blood"},{"key":"2711_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20:15.","journal-title":"Mol Cancer"},{"key":"2711_CR45","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9:910\u201325.","journal-title":"Cancer Discov"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02711-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:04:42Z","timestamp":1757264682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02711-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02711-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SL declares research support from Amgen and Astellas and consulting fees from AbbVie, AlphaSight, Arima, Blueprint Medicine, BMS, Caris, Daiichi-Sankyo, Gerson Lehrman Group, Guide Point, Immunogen, Kura Oncology, QualWorld, Recordati, Servier, Stemline Syndax, and Tempus AI. KS declares honoraria from Otsuka Pharma and a consultancy fee from Pfizer Japan. HK declares research support from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer, honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda, and an advisory role with Actinium. GG-M declares support from and an advisory role with Celgene Corporation, Astex, and Amphivena, and grant\/research support 15 from Helsinn, Novartis, AbbVie, Onconova, H3 Biomedicine, and Merck. The rest of the authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods described in this manuscript were performed in accordance with the relevant guidelines and regulations. The study protocols reported in this manuscript were conducted in accordance with the Declaration of Helsinki. Patients who donated bone marrow aspiration samples provided written consent in accordance with the biobanking study protocol, which was approved by the University of Texas MD Anderson Cancer Center Review Board under protocol LAB-01-743. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}